ClinicalTrials.gg
TerminatedNCT00350519Updated Jul 22, 2013Results posted

The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery

A Phase 4 interventional study of Epoetin alfa and Standard of Care in Hemostasis, Surgical, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-22.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Why this study was terminated
The study was stopped due to slow enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary purpose of the study is to compare the effect of perioperative (the time period describing the duration of a participants surgical procedure) administration of PROCRIT to that of Standard of Care (SOC) on the proportion of participants receiving pRBC (packed red blood cells) transfusions (from the day of surgery to the day of hospital discharge) in participants undergoing elective major abdominal and/or pelvic surgery. Standard of Care is defined as the treatment of participants according to the hospital or institution's policy, but where participants will not receive PROCRIT (Epoetin alfa) or any other erythropoiesis-stimulating agents (ESAs) (agents that stimulate the production of red blood cells in the bone marrow).

Read the detailed description

This is a randomized (the study medication is assigned by chance), parallel-arm (each group of participants will be treated at the same time), open-label (all people know the identity of the intervention), multicenter study. The study consists of screening phase of 21 days, treatment phase of 15 days, follow-up phase of 28 days. Approximately 110 participants undergoing elective major abdominal and/or pelvic surgery will be enrolled. During the Treatment Phase, eligible participants will be randomly assigned (participants are assigned to a treatment group based on chance) in a 1:1 ratio to either PROCRIT (Epoetin alfa) or the Standard of Care (SOC) group that will not receive any erythropoiesis-stimulating agents (ESAs). Participants will undergo surgery during the Treatment Phase. After surgery, all participants will stay in the study for 4 days (or until hospital discharge) and followed for an additional 28 days (Follow-up Phase). Safety evaluations will include assessment of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination which will be monitored throughout the study. The duration of the study for each participant will be approximately 64 days.

02

Conditions studied

  • Hemostasis, Surgical

Keywords

  • Hemostasis, Surgical
  • Epoetin alfa
  • Surgery
  • Abdomen
  • Pelvis
  • PROCRIT
  • pRBC
  • Blood transfusion
  • Packed red blood cell transfusion
03

In context

Lead sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Scheduled to undergo elective major abdominal and/or pelvic surgery with anticipated significant perioperative ((the time period describing the duration of a participants surgical procedure) blood loss (eg, greater than 500 cc and at increased risk for blood transfusion) - greater than 10 g/dL and less than or equal to 13 g/dL at screening (Day -13 [13 days prior to surgery] to Day -11) and baseline (Day -10) - Patients with and their partners must practice an effective method of (eg, prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, partner sterilization) before entry and throughout the study - Female patients with reproductive potential must have a negative urine pregnancy test within 7 days of the first dose of PROCRIT - Adequate renal (kidney) and adequate hepatic (liver) function assessed within the 21-day screening period Exclusion Criteria: - No severe Congestive Heart Failure ( Class IV) - No known severe stable or unstable coronary artery disease, or unstable angina - No history of deep venous thrombosis (DVT) or pulmonary embolus (PE) within 12 months before study entry (prior superficial thrombophlebitis is not an exclusion criterion) - No history of cerebrovascular accident (CVA), (TIA), Acute coronary syndrome (unstable Angina, myocardial Infarction), or other arterial thrombosis within 6 months before study entry - Not anticipated to donate perioperative autologous blood or receive transfusions within 21 days prior to baseline or to have greater than 6 transfusions perioperatively - No prior treatment with PROCRIT or any erythropoiesis-stimulating agents (ESAs) within the previous month

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    PROCRIT (epoetin alfa)

    Participants will receive PROCRIT (epoetin alfa).

    Drug: Epoetin alfa

  • Experimental
    STANDARD THERAPY

    Participants will receive standard of care.

    Drug: Standard of Care

Interventions

  • Participants will receive epoetin alfa 300 IU/kg once daily subcutaneously for 10 days prior to surgery, on the day of surgery, and for four days after surgery.

    Also known as: PROCRIT

  • DrugStandard of Care

    Participants will receive standard of care based on the Institution's treatment policy.

06

What researchers measure

Primary outcomes

  1. Number of Participants Receiving pRBC (Packed Red Blood Cell) Transfusions

    Time frame: Day of surgery until hospital discharge

Secondary outcomes

  1. Hemoglobin Change From Baseline to End of Study

    End of Study Hemoglobin minus baseline Hemoglobin

    Time frame: Baseline (Day-10) to end of study (Day 32)

  2. Number of pRBC Units Transfused During Study

    Time frame: Baseline (Day -10) to end of study (Day 32)

  3. Hospital Length of Stay

    Time frame: Surgery to hospital discharge

07

Results

Posted May 6, 2009
Limitations and caveats
No formal analysis was conducted due to early termination.

Participant flow

Participant flow — Overall Study
MilestonePROCRIT (Epoetin Alfa)STANDARD THERAPY
Started1819
Completed1413
Not completed46
Withdrew: Death01
Withdrew: Physician decision01
Withdrew: Protocol violation12
Withdrew: Withdrawal by subject32

Outcome measures

PrimaryNumber of Participants Receiving pRBC (Packed Red Blood Cell) Transfusions
Time frame:
Day of surgery until hospital discharge
Reported as:
Number · participants
Number of Participants Receiving pRBC (Packed Red Blood Cell) Transfusions
participantsPROCRIT (Epoetin Alfa)STANDARD THERAPY
Number of Participants Receiving pRBC (Packed Red Blood Cell) Transfusions49
SecondaryHemoglobin Change From Baseline to End of Study

End of Study Hemoglobin minus baseline Hemoglobin

Time frame:
Baseline (Day-10) to end of study (Day 32)
Reported as:
Mean · g/dL
Hemoglobin Change From Baseline to End of Study
g/dLPROCRIT (Epoetin Alfa)STANDARD THERAPY
Hemoglobin Change From Baseline to End of Study0.98 ± 1.390.33 ± 2.06
SecondaryNumber of pRBC Units Transfused During Study
Time frame:
Baseline (Day -10) to end of study (Day 32)
Reported as:
Mean · units
Number of pRBC Units Transfused During Study
unitsPROCRIT (Epoetin Alfa)STANDARD THERAPY
Number of pRBC Units Transfused During Study3.5 ± 3.006.11 ± 7.98
SecondaryHospital Length of Stay
Time frame:
Surgery to hospital discharge
Reported as:
Mean · days
Hospital Length of Stay
daysPROCRIT (Epoetin Alfa)STANDARD THERAPY
Hospital Length of Stay7.94 ± 5.1712.56 ± 12.30

Adverse events

Collected over 64 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PROCRIT (Epoetin Alfa)—5/18 (27.8%)18/18 (100%)
STANDARD THERAPY—8/19 (42.1%)13/19 (68.4%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPROCRIT (Epoetin Alfa)STANDARD THERAPY
Postoperative ileusInjury, poisoning and procedural complications2/180/19
Failure to thriveMetabolism and nutrition disorders0/182/19
Abdominal abscessInfections and infestations1/180/19
Wound dehiscenceInjury, poisoning and procedural complications1/180/19
Renal failureRenal and urinary disorders1/180/19
Ureteric obstructionRenal and urinary disorders1/180/19
Pleural effusionRespiratory, thoracic and mediastinal disorders1/180/19
Device dislocationInjury, poisoning and procedural complications0/181/19
Anticoagulation drug level below therapurticInvestigations0/181/19
International normalized ratio increasedInvestigations0/181/19
Most frequent other events
Showing 10 of 90
Most frequent other events
EventPROCRIT (Epoetin Alfa)STANDARD THERAPY
PyrexiaGeneral disorders2/187/19
NauseaGastrointestinal disorders6/186/19
Procedural hypotensionInjury, poisoning and procedural complications3/185/19
Procedural painInjury, poisoning and procedural complications2/185/19
VomitingGastrointestinal disorders4/182/19
HypotensionVascular disorders4/181/19
CoughRespiratory, thoracic and mediastinal disorders3/182/19
Procedural hypertensionInjury, poisoning and procedural complications1/183/19
HyperglycaemiaMetabolism and nutrition disorders1/183/19
TachycardiaCardiac disorders2/182/19

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PROCRIT (Epoetin Alfa)STANDARD THERAPYTotal
<=18 years000
Between 18 and 65 years111223
>=65 years7714
Age Continuous
Age Continuous(years)PROCRIT (Epoetin Alfa)STANDARD THERAPYTotal
Mean63.06 ± 16.1761.42 ± 18.3262.22 ± 17.08
Sex: Female, Male
Sex: Female, Male(Participants)PROCRIT (Epoetin Alfa)STANDARD THERAPYTotal
Female131023
Male5914
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PROCRIT (Epoetin Alfa)STANDARD THERAPYTotal
Black or Aftrican American055
Other123
White171229
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2006
First posted
Jul 10, 2006
Start
Aug 2006
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
May 6, 2009
Last update
Jul 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00350519
Collaborators
Ortho Biotech Clinical Affairs, L.L.C.
Responsible party
Sponsor
First posted
Jul 10, 2006
Start date
Aug 2006
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
May 6, 2009
Last update
Jul 22, 2013

Study contacts

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion